389 results about "Fucose" patented technology

The invention provides infant formula milk powder for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the infant formula milk powder. The invention provides infant formula milk powder for the first time, the infant formula milk powder comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The infant formula milk powder can improve intestinal inflammation and / or microbial disorder.

The invention discloses application of a ganoderma lucidum strain SS30 in preparation of a product for treating cancers, and belongs to the technical field of biology. The invention provides ganoderma lucidum strain SS30 mycelium polysaccharide. The ganoderma lucidum strain SS30 mycelium polysaccharide is prepared from glucose, galactose, mannose, fucose, xylose, arabinose, rhamnose, glucuronic acid, glucosamine, ribose and lacturonic acid. The polysaccharide has a remarkable effect of inhibiting transplantable pancreatic cancer and primary colorectal cancer, can achieve the effect of treating cancer by improving the immune function and reducing the oxidation product generation level, provides a new material for development and utilization of lucid ganoderma and products thereof, and has a wide application prospect. And a research basis is provided for research and development of cancer-related drugs and research of a cancer treatment mechanism.

The invention discloses a normal-temperature bacteria liquid enteric-coated targeted colonization microcapsule and a preparation method thereof. The invention belongs to the technical field of biological medicine. The structure of the room-temperature bacterial liquid protection microcapsule is as follows: an inner layer is an activity maintaining layer and mainly consists of a sodium alginate-calcium chloride polyelectrolyte compound (the thickness is 50-100 microns); the middle layer is a pH response release layer and is mainly composed of hydroxypropyl methyl cellulose phthalate (HPMCP, dissolved at pH of 6.8 or above) and nano calcium carbonate particles (the particle size is 50nm, and the proportion is 10% w / w); the outer layer is a mucous membrane adhesion layer, and the main components of the mucous membrane adhesion layer comprise fucose modified chitosan (Fuc-CS, targeted colonic mucous membrane lectin protein) and carbomer 940 (pH sensitive adhesion polymer); the method is a microcapsule capable of preserving the bacterial liquid at normal temperature and accurately targeting colon release and adhesion colonization and a process thereof, the problem of flora activity loss caused by a freeze-drying process can be solved, in addition, the process does not need freeze-drying equipment, and the production cost is reduced.

The invention provides a children formula food for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the children formula food. The invention firstly provides the infant formula food, the infant formula food is infant formula food or child formula food, the infant formula food comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The children formula food can improve intestinal inflammation and / or microbial disorder.

The invention belongs to the field of food, and particularly relates to a nutritional composition containing breast milk oligosaccharide and probiotics for improving depression and application of the nutritional composition. The invention provides application of a nutritional composition in preparation of food beneficial to improving constipation and anxiety state and / or depression state caused by constipation. Wherein the nutritional composition comprises the following components (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, and (ii) a bifidobacterium probiotic; the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the bifidobacterium probiotics at least comprise bifidobacterium longum subsp. Longum. According to the present invention, the substance combination of the neutral fucosylated breast milk oligosaccharide and the bifidobacterium probiotic can improve the abnormal brain-intestine interaction, such that the constipation can be easily improved, and the anxiety and depression state caused by the constipation can be easily improved;

The invention belongs to the field of food, and particularly relates to a nutritional composition of oligosaccharide and probiotics and application of the nutritional composition. The invention provides application of a nutritional composition in preparation of food beneficial to improvement of constipation and improvement of cognitive competence decline caused by constipation. Wherein the nutritional composition comprises the following components (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, and (ii) a bifidobacterium probiotic; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the bifidobacterium probiotics at least comprise bifidobacterium longum subsp. Longum. According to the present invention, with the substance combination of the neutral fucosylated breast milk oligosaccharide and the bifidobacterium probiotic, the abnormal brain-intestine interaction can be improved, such that the constipation can be easily improved, and the cognitive ability reduction caused by the constipation can be easily improved;

The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.

The present invention discloses a preparation method of Inonotus hispidus polysaccharide IHP-1aa: It is obtained by removing fat with ethanol, extracting with water and precipitating with ethanol, then removing proteins by the Sevage method, separating neutral polysaccharide components through a DEAE-52 cellulose column and a DEAE agarose gel column, and finally purifying with Sephadex G-100. The Inonotus hispidus polysaccharide has uniform purity and clear composition, and is a heteropolysaccharide composed of glucose, galactose, mannose, fucose and methylgalactose, with a molecular weight of 26.9 kDa. In vitro experiments show that it has no adverse effects on normal cells, can significantly stimulate macrophages RAW264.7 to secrete NO, IL-6 and TNF-α, has good immunomodulatory activity, and can be used for the development of immunomodulatory products.

The invention belongs to the field of food, and particularly relates to application of a nutritional composition for assisting in improving memory ability. The invention provides application of a nutritional composition in preparation of food for assisting in improving memory ability of offspring. The nutritional composition comprises the following necessary components: active folic acid substances and fucosyllactose, moreover, in the nutritional composition, the mass ratio of the active folic acid substance to the fucosyllactose is (0.0001-0.0015): (0.5-10), the food is ingested by a mother to play the role of assisting in improving the memory ability of the offspring, the mother is in a gestation period and / or a lactation period, and the maternal is in the gestation period and / or the lactation period. The filial generation comprises a fetal-stage filial generation and / or an infant-stage filial generation and an optional child-stage filial generation. A large number of studies find that when active folic acid substances and fucosyllactose which are combined according to a certain proportion are supplemented to a mother at the beginning of the gestation period, the memory ability of offspring can be remarkably improved in an auxiliary mode.

The invention discloses cubilose sialic acid glycan peptide capable of improving lung inflammation and application of the cubilose sialic acid glycan peptide. The ratio of fucose modified sugar chains in the cubilose sialic acid glycan peptide is 30-60%, the ratio of sialic acid modified sugar chains in the cubilose sialic acid glycan peptide is 20-40%, the core structure of the fucose type is (HexNAc) 3 (Man) 3 (Fuc) 1, the core structure of the sialic acid type is (HexNAc) 3 (Man) 3 (Gal) 1 (Fuc) 1 (NeuAc) 1, the neutral sugar dissolution rate of the cubilose sialic acid glycan peptide is high, and the glycopeptide shown in SEQ ID NO 2 has a good inflammation improving effect.

The invention discloses recombinant escherichia coli capable of increasing the yield of fucosyllactose and a construction method and application of a fucosyltransferase mutant of the recombinant escherichia coli, and belongs to the field of synthetic biology and metabolic engineering. According to the invention, recombinant escherichia coli B20 and B21 are constructed based on key enzyme engineering transformation. Under the shake flask condition, the 3-FL production capacity of the recombinant strain is obviously improved to 6.20 g / L and 6.34 g / L from the initial 3.45 g / L, and the amplification reaches 79.7% and 83.8% respectively. The yields of 3-FL of the strain B20 and the strain B21 respectively reach 53.88 g / L and 54.64 g / L under the culture condition of a 3L fermentation tank. The recombinant escherichia coli for expressing the 2 '-FL is constructed, and the yield of the 2'-FL reaches 64.86 g / L in a 3L fermentation tank. The invention provides a new technical scheme for efficient microbial synthesis of the 3-FL.

The use of a nutritional composition in the preparation of a food product for assisting in improving the memory ability in offspring, wherein the nutritional composition contains the following essential components: an active folic acid substance and fucosyllactose; and in the nutritional composition, the mass ratio of the active folic acid substance to the fucosyllactose is (0.0001-0.0015):(0.5-10). The food product exerts the effect of assisting in improving the memory ability in offspring, wherein the food product is ingested by a mother, the mother is preganant and / or lactating, and the offspring comprises fetal offspring and / or infant offspring and optionally childhood offspring.

The invention belongs to the technical field of food engineering, and particularly relates to an anti-allergic special medical infant milk protein partial hydrolysis formula food composition, a preparation method and application. According to the infant milk protein partial hydrolysis formula food composition for the special medical purpose, the mass ratio of the 2 '-fucosyllactose to the lactobacillus acidophilus NCFM to the bifidobacterium animalis Bi-07 is (150-200): (5-10): (2-8). The partially hydrolyzed formula food composition provided by the invention can prevent respiratory tract infection and maintain the natural defense capability of children; the infant health is promoted; the method helps infants to establish healthy intestinal microflora, which is crucial to immune system and cognitive development.

The invention discloses recombinant yarrowia lipolytica with high yield of 3-fucosyllactose as well as a construction method and application of the recombinant yarrowia lipolytica. According to the invention, a reinforced lactose transporter lac12 gene, a reinforced GDP-mannose-4, 6-dehydratase gmd gene, a reinforced GDP-L-fucose synthase gmer gene and a 3-fucosyltransferase SUMO-fut3Bc gene with a reinforced SUMO tag are subjected to integrated expression on a recombinant yarrowia lipolytica chromosome, and a 6-phosphogluconolactonase pgl gene is subjected to overexpression, so that a recombinant yarrowia lipolytica strain is obtained. The constructed recombinant yarrowia lipolytica can maintain the genetic stability of a target gene, the yield and production efficiency of 3-fucosyllactose are remarkably improved, and the requirements of industrial production can be met.

The invention belongs to the field of functional substance research, and particularly relates to a nutritional composition for promoting absorption of fatty acid and mineral substances and application. The nutritional composition provided by the invention comprises necessary active ingredients shown as the following (I) and (II): (I) 1, 3-dioleic acid-2-palmitic acid triglyceride; (II) a milk fat globule membrane, and / or, 2 '-fucosyllactose; moreover, in the nutritional composition, the mass ratio of the necessary active component shown in (I) to the necessary active component shown in (II) is (5-10): (0.5-10). The combination of OPO and MFGM and / or 2 '-FL provided by the invention can be beneficial to promoting the absorption of the body to fatty acids and mineral substances, and especially can be beneficial to promoting the transmembrane transport capability of intestinal cells of the body to fatty acids and mineral substances, so that the absorption efficiency is improved.

The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or nutritional compositions comprising the combination. The combination or compositions are for use in treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child. The mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL). The present invention also relates to the use of a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child, wherein the mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL).

The invention belongs to the technical field of nutritional compositions, and discloses a breast milk oligosaccharide-containing composition for promoting brain metabolism and relieving diarrhea and application of the breast milk oligosaccharide-containing composition, and the breast milk oligosaccharide-containing composition contains breast milk oligosaccharide consisting of 2 '-fucosyllactose, 3'-sialic acid lactose and 6 '-sialic acid lactose in a specific weight ratio. The composition disclosed by the invention is used for preparing products with the functions of promoting brain development or metabolism and relieving diarrhea. The composition prepared by the invention can be used for preparing formula milk powder, yoghourt and various metabiotics preparations with corresponding effects.

The present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual wherein the composition comprises Bifidobacterium longum subsp. Infantis and a mixture of HMO consisting of 2 '-fucosyllactose (2FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6'-sialyllactose (6SL), 3 '-sialyllactose (3SL), and 3-fucosyllactose (3FL). The present invention also provides compositions for use in preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing respiratory disorders in an individual, and / or preventing and / or reducing the risk of developing asthma in an individual.

The present invention relates to a composition for infants or young children comprising at least one probiotic strain and a prebiotic mixture of human milk oligosaccharides, said probiotic strain being Bifidobacteria, the present invention relates to a composition comprising a prebiotic mixture of human milk oligosaccharides consisting of 2 '-fucosyllactose (2FL), milk difucosyltetraose / difucosyllactose (DFL), milk-N-tetraose (LNT), 6'-sialyllactose (6SL), 3 '-sialyllactose (3SL) and optionally 3-fucosyllactose (3FL), which composition is useful for (i) preventing and / or treating a bacterial infection in an infant or a young child; (ii) modulate the microbiota in the infant or young child; and / or iii) preventing and / or treating allergies in infants or young children.

The present invention relates to a composition comprising a Bifidobacterium longum transitional microorganism and a mixture of human milk oligosaccharides (HMOs) consisting of 2'-fucosyllactose (2'-FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), and 3'-sialyllactose (3SL), and optionally lacto-N-fucopentaose I (LNFP-I), 3- fucosyllactose (3-FL) and / or lacto-N-neotetraose (LNnT), wherein the Bifidobacterium longum transitional microorganism has an Average Nucleotide Identity (ANI) of at least 98% with CNCM I-5942. The invention also relates to the use of the composition for preventing, reducing the risk of and / or treating an infection in a subject. The invention also provides the composition for use in promoting a long-term immune benefit in a subject, preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.

The present disclosure relates to a composition for balancing the immune system of a neonatal or infant subject, the composition comprising an effective amount of 2 '-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6 '-sialyllactose, and lactose-N-tetrasaccharide.

The invention relates to Escherichia coli for producing 2 '-fucosyllactose as well as a construction method and application of the Escherichia coli, and belongs to the technical field of genetic engineering. A CRISPR / Cas9 system is used for transforming a genome of escherichia coli MG1655, a wcaJ gene and a lacZ gene are knocked out, the utilization rate of lactose and GDP-L-fucose in a metabolic pathway is increased, a promoter of a lacY gene is replaced with PJ23119, an alpha-1, 2-fucosyltransferase mutant with a dissolution promoting tag GST added to the N end is heterologously introduced, the expression quantity of the alpha-1, 2-fucosyltransferase mutant is increased through multi-copy integration, and the expression quantity of the alpha-1, 2-fucosyltransferase mutant is increased. Meanwhile, a gmd gene, an fcl gene, a manB gene and a manC gene are co-expressed at proper sites, so that the synthesis route of the GDP-L-fucose is optimized. The strain obtained through transformation can efficiently convert lactose into 2 '-FL and has the advantages of being low in metabolic burden, sufficient in precursor supply, high in enzyme stability and the like, the construction method is clear in step and suitable for industrial production, the yield of 2'-FL can be remarkably increased through microbial agents and fermentation application, and the production cost is reduced.

The invention relates to a gene modified cell for producing HMOs, which can be applied to synthesis of difucosyllactose, and belongs to the technical field of gene engineering. The invention provides a genetically modified cell, which contains an alpha-1, 2-fucosyltransferase polypeptide and a heterologous nucleic acid sequence of the alpha-1, 3-fucosyltransferase polypeptide. The genetically modified cell has higher activity of synthesizing difucosyllactose, and does not contain synthetic 3-fucosyllactose or lower side activity of synthetic 2 '-fucosyllactose. The technical scheme of the invention has positive significance for industrial production of human milk oligosaccharide, and the method is green, efficient and sustainable, is beneficial to industrial large-scale production, and has important practical value.

The application discloses a composition for improving asthenopia and application, and the composition is compounded by longissimum bifidobacterium longum subsp i772, 2'-fucose lactose, lacto-N-neotetraose and lutein with a weight ratio of 1-100:460-1600:120-400:0.03-0.35. The composition for improving asthenopia has a synergistic effect in the function of relieving asthenopia, longissimum bifidobacterium longum subsp i772, 2'-fucose lactose, lacto-N-neotetraose and lutein can effectively relieve the apoptosis of eye cells caused by asthenopia, and the composition can be applied to infant formula milk powder, children's formula milk powder, fermented milk and health food.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

Provided herein are host cells capable of producing a human milk oligosaccharide (HMO), such as yeast cells that include one or more heterologous nucleic acids encoding one or more enzymes of the HMO biosynthetic pathway, such as a fucosyltransferase, GDP-mannose dehydratase, lactose permease, and / or fucose synthase. Also provided are fermentation compositions including the disclosed host cells, as well as related methods of producing and recovering HMOs generated by the host cells.

The use of 2'-fucosyllactose in the preparation of a food / drug for promoting intestinal glycocalyx development and preventing intestinal glycocalyx damage caused by lipopolysaccharide (LPS). The use of 2'-fucosyllactose in the preparation of a food / drug for the adjuvant treatment and / or adjuvant prevention of gastrointestinal infections, inflammatory bowel diseases, obesity or allergy caused by glycocalyx damage. Before adherent growth of Caco-2 cells, adding 2'-FL for co-culture with the Caco-2 cells can simulate the intestinal growth and maturation state. In the state, 2'-FL can significantly promote the development of the glycocalyx layer of Caco-2 cells, and can further prevent the glycocalyx layer damage caused by LPS on this basis.

The invention provides a series of GDP-mannose dehydratase polypeptides which can be applied to synthesis of GDP-fucose, and belongs to the technical field of enzyme engineering. The GDP-mannose dehydratase polypeptide comprises a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to that of a polypeptide shown in SEQ ID NO: 1, or a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to that of a polypeptide M1-13. The GDP-mannose dehydratase polypeptide disclosed by the invention has relatively high catalytic activity.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

The present application relates to a series of GDP-fucose synthetase polypeptides, which can be applied to the synthesis of human milk oligosaccharides (HMOs) precursor GDP-fucose, belonging to the field of enzyme engineering technology. In certain embodiments, the polypeptide having catalytic GDP-4-keto-6-deoxymannose converted into GDP-fucose comprises an amino acid sequence which is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identical to SEQ ID NO: 1 and / or to the polypeptide M1-14. The present application provides a series of polypeptides for synthesizing GDP-fucose.